ClinicalTrials.Veeva

Menu

Vitamin B12 Status and Its Impact on Chronic Haemodialysis Patient

A

Assiut University

Status

Not yet enrolling

Conditions

Vitamin B 12 Deficiency
End Stage Renal Disease on Dialysis

Treatments

Device: Vitamin b12 measure

Study type

Observational

Funder types

Other

Identifiers

NCT06441721
Vitamin B12 and Haemodialysis

Details and patient eligibility

About

To evaluate vitamin B12 level in haemodialysis patients and its impact on hematological and neurological manifestations

Full description

Vitamin B12 (cobalamin) is a water-soluble vitamin involved in several normal cellular functions (1). Vitamin B12 is required for the development, myelination, and function of the central nervous system; healthy red blood cell formation; and DNA synthesis (2- 4). Low levels of vitamin B12 have been associated with high concentrations of homocysteine (Hcy) and can lead to health complications (5). Hyperhomocysteinemia is an important risk factor for cardiovascular disease (6). Vitamin B12 and other B vitamins are involved in homocysteine metabolism, and researchers have hypothesized that supplementation with these micronutrients can reduce the risk of cardiovascular disease by lowering homocysteine levels (7, 8). Vitamin B12 deficiency is one of the causes of Macrocytic anaemia with increased mean corpuscular volume (MCV), defined as more than 100 fL, which is the hallmark of megaloblastic anaemia

Enrollment

60 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • End stage renal disease on haemodialysis pts.
  • Parients more than 18 years .
  • CKD patients controled group stage 3and stage 4.

Exclusion criteria

  • Recent renal transplantation patients.
  • Patients on sulpha drugs.
  • Patients on methotrexate.
  • Patients on anticonvulsant.
  • Patients on chemotherap agent.
  • Patients on colchicine.
  • Patients on bile acid sequestrant.
  • Patients on h2blockers.
  • Patients on metformin.
  • Patients on proton pump inhibitors .
  • Diabetic patients.
  • Parients with history of intestinal surgery.
  • Patients diagnosed with malabsorption syndrome.
  • Patient on vitamin b12 intake.

Trial contacts and locations

0

Loading...

Central trial contact

Afaf bakry amin, Resident; Alaa Eldin Abd Elmoniem, supervisor

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems